Bio-Techne Corporation (TECH) Host Conference Call On To Announce Fourth Quarter Financial Results


Bio-Techne To Host Conference Call On August 8, 2017 To Announce Fourth Quarter Financial Results

Access to the discussion may be obtained as follows:
Time:     8:00 a.m. CDT
Date:      August 8, 2017
Dial-in:   1-888-287-5516 or 1-719-457-2683 (for international callers)
Conference ID: 8032349

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call.  To access the recording, U.S. callers should dial 1-844-512-2921 or international callers should dial 1-412-317-6671 and enter the replay access code 8032349. The recording can also be accessed by going to:

The replay will be available from 11:00 a.m. CDT on Tuesday, August 8, 2017 until 11:00 p.m. CDT on Friday, September 8, 2017.

Bio-Techne Corporation (TECH) is a leading developer and manufacturer of high quality purified proteins––notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds — which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotech Division, headquartered in Minneapolis, Minnesota.  The Protein Platform Division manufactures innovative protein analysis tools under the ProteinSimple brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls for OEM customer and clinical customers. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $499 million in net sales in fiscal 2016 and has approximately 1,700 employees worldwide. For more information on Bio-Techne and its brands, please visit


Please enter your comment!
Please enter your name here